You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Recent awards include:
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.
At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.
EyeGate prices $10M common stock, warrants offering
Identifying PPE Suppliers During the Pandemic
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021
Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective
Eyegate Pharmaceuticals Inc. is looking to raise $10 million via a public offering.
The company will issue 6,666,667 shares at $1.50 apiece, complete with warrants to purchase an additional 6,666,667 stock within five years from the date of issue at the same price.
EyeGate plans to use the net proceeds for clinical trials, working capital and general corporate purposes.
Rodman & Renshaw is acting as the exclusive placement agent for the offering which is expected to close by June 14.